查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1705432

2025年多种癌症早期检测全球市场报告

Multi Cancer Early Detection Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年多种癌症早期检测市场规模将快速成长。到 2029 年，这一数字将成长至 34.9 亿美元，复合年增长率为 19.1%。预测期内的增长可归因于远端医疗健康的扩展、对预防性医疗保健的日益重视、精准肿瘤学的日益普及、生物标誌物发现的进步以及直接面向消费者的基因检测的激增。预测期内的关键趋势包括人工智慧和机器学习的使用日益增多、液态切片技术的采用日益增多、多组体学方法的整合、家用检测套组的扩展、对早期癌症检测的日益关注以及微创诊断方法的开发。

个人化医疗的日益普及将有助于未来扩大多种癌症早期检测市场。个人化医疗是根据个人的特征和基因组成客製化医疗干预措施，由于可以改善治疗效果而越来越受欢迎。这一趋势受到基因组学的进步、疾病复杂性的增加以及支持性法律规范的推动。个人化医疗透过根据个人的基因和生物标记情况客製化筛检和治疗方法，提高了多种癌症早期发现的有效性。例如，FDA 于 2024 年 2 月核准的针对罕见疾病的新型个人化治疗方法的数量从 2022 年的 6 种增加到 16 种。因此，个人化医疗的接受度不断提高正在推动多癌症早期检测市场的成长。

多癌症早期检测市场的主要企业正在创新基于 ctDNA 的液态切片测试，以提高敏感性、特异性和早期检测率，最终带来更好的患者治疗效果。这些测试可检测血液中的循环肿瘤 DNA，并提供一种非侵入性的方法来追踪肿瘤动态、治疗反应、早期復发和微量残存疾病。例如，2023年5月，美国癌症诊断公司Lucence在其美国总部推出了开创性的多癌症早期检测（MCED）血液测试LucenceINSIGHT。这种基于 ctDNA 的液态切片测试可以透过单一血液样本筛检10 种常见癌症类型。全球约 78% 的癌症死亡与没有常规筛检通讯协定的癌症类型有关，这种血液检测为寻求筛检多种癌症类型的无症状人群提供了便利和更高的可及性。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球多种癌症早期检测PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球多种癌症早期检测市场：成长率分析
  • 全球多癌种早期检测市场表现：规模与成长，2019-2024
  • 全球多种癌症早期检测市场预测：规模与成长，2024-2029 年，2034 年
  • 全球多种癌症早期检测总目标市场（TAM）

第六章市场区隔

  • 全球多种癌症早期检测市场（按类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 液态生物检体
  • 基因面板
  • 实验室检查（LDT）
  • 其他类型
  • 全球多癌种早期检测市场（依癌症类型、表现及预测）2019-2024 年、2024-2029 年及 2034 年
  • 固态肿瘤
  • 造血系统恶性肿瘤
  • 全球多癌种早期检测市场：依最终用户、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 诊断实验室
  • 其他最终用户
  • 全球多癌种早期检测市场，依液态生物检体类型细分，依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 循环性肿瘤细胞（CTC）
  • 循环肿瘤DNA（CtDNA）
  • 外泌体
  • 全球多癌种早期检测市场、基因面板细分、类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 基于DNA的面板
  • 基于RNA的面板
  • 多基因面板
  • 全球多癌种早期检测市场，按实验室检测 (LDT) 类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • PCR检测
  • 次世代定序（NGS）检测
  • 免疫组织化学（IHC）测试
  • 全球多癌种早期检测市场，按类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 蛋白质生物标记
  • 基于自身抗体的检测

第七章 区域和国家分析

  • 全球多种癌症早期检测市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球多癌种早期检测市场：依国家/地区、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 多癌种早期检测市场：竞争格局
  • 多癌症早期检测市场：公司简介
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Natera Inc Overview, Products and Services, Strategy and Financial Analysis
    • Guardant Health Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Core Diagnostics
  • Genecast Biotechnology Co. Ltd
  • Burning Rock Biotech Limited
  • Freenome Holdings Inc.
  • Guangzhou AnchorDx Medical Co. Ltd
  • Singlera Genomics Incorporated
  • Naveris Inc.
  • Lucence Health Inc.
  • PredOmix Technologies
  • Micronoma INC.
  • EarlyDiagnostics（EarlyDx）
  • Elypta AB
  • Predictive Oncology
  • ANPAC Bio-Medical Science Co. Ltd
  • CanSense Ltd

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年多癌症早期检测市场：提供新机会的国家
  • 2029年多癌种早期检测市场：细分领域带来新机会
  • 2029年多癌症早期检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r30742

Multi-cancer early detection involves identifying and diagnosing various cancer types in their early stages through the examination of biomarkers and other indicators present in bodily fluids or tissues. The objective is to detect cancerous conditions affecting multiple organs or tissues before symptoms appear, thereby facilitating prompt intervention and enhancing treatment effectiveness.

The primary categories of multi-cancer early detection include liquid biopsy, gene panels, laboratory-developed tests (LDT), and other methodologies. Liquid biopsy, for instance, is a non-invasive diagnostic procedure that identifies cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids such as blood or urine. These tests provide valuable information on cancer detection, progression, and response to treatment. They are utilized across hospitals, diagnostic facilities, and other medical settings for diagnosing various cancer types, including both solid tumors and hematological malignancies.

The multi cancer early detection market research report is one of a series of new reports from The Business Research Company that provides multi cancer early detection market statistics, including the multi cancer early detection industry global market size, regional shares, competitors with multi cancer early detection market share, detailed multi cancer early detection market segments, market trends, and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. This multi cancer early detection market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multi cancer early detection market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, government initiatives and funding, growing awareness about early cancer detection, expansion of healthcare infrastructure, rising adoption of personalized medicine, decreasing costs of genetic testing.

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to expansion of telemedicine and digital health, growing emphasis on preventive healthcare, increasing adoption of precision oncology, advances in biomarker discovery, surge in direct-to-consumer genetic testing. Major trends in the forecast period include increasing use of AI and machine learning, growing adoption of liquid biopsy techniques, integration of multi-omics approaches, expansion of at-home testing kits, rising focus on early-stage cancer detection, development of minimally invasive diagnostics.

The increasing adoption of personalized medicine is poised to drive the expansion of the multi-cancer early detection market in the future. Personalized medicine, which customizes healthcare interventions based on individual characteristics and genetic makeup, is gaining traction due to its ability to enhance treatment efficacy. This trend is fueled by advancements in genomics, the growing complexity of diseases, and supportive regulatory frameworks. Personalized medicine amplifies the effectiveness of multi-cancer early detection by tailoring screening and treatment approaches to individual genetic and biomarker profiles. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, including seven cancer treatments and three for various other conditions, as reported by the Personalized Medicine Coalition. Hence, the increasing embrace of personalized medicine is fostering growth in the multi-cancer early detection market.

Major companies in the multi-cancer early detection market are innovating ctDNA-based liquid biopsy tests to improve sensitivity, specificity, and early detection rates, ultimately enhancing patient outcomes. These tests detect circulating tumor DNA in the bloodstream, offering a non-invasive method to track tumor dynamics, treatment response, and early recurrence or minimal residual disease. For example, in May 2023, Lucence, a US-based cancer diagnostics firm, unveiled LucenceINSIGHT, a pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. This ctDNA-based liquid biopsy test enables screening for 10 common cancers using a single blood sample. With approximately 78% of global cancer deaths linked to types lacking routine screening protocols, this blood test offers improved convenience and accessibility for asymptomatic individuals seeking screening for various cancer types.

In May 2023, Freenome Holdings Inc., a US-based biotechnology company, acquired Oncimmune Ltd. for an undisclosed sum. This acquisition is aimed at enhancing Freenome's early cancer detection capabilities by incorporating Oncimmune's autoantibody platform and expanding its multiomics portfolio. Oncimmune Ltd., a UK-based biotechnology firm, specializes in immunodiagnostics for cancer detection.

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Naveris Inc. , Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx

North America was the largest region in the multi cancer early detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multi cancer early detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multi-cancer early detection market consists of revenues earned by entities by providing services such as diagnostic imaging, screening tests, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of assay panels, diagnostic kits, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multi Cancer Early Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multi cancer early detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multi cancer early detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multi cancer early detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Liquid Biopsy; Gene Panel; Laboratory Developed Tests (LDT); Other Types
  • 2) By Cancer Type: Solid Tumors; Hematological Malignancies
  • 3) By End-User: Hospitals; Diagnostic Laboratories; Other End Users
  • Subsegments:
  • 1) By Liquid Biopsy Types: Circulating Tumor Cells (CTC); Circulating Tumor DNA (Ctdna); Exosomes
  • 2) By Gene Panel: DNA-Based Panels; RNA-Based Panels; Multi-Gene Panels
  • 3) By Laboratory Developed Tests (LDT): PCR-Based Tests; Next-Generation Sequencing (NGS) Tests; Immunohistochemistry (IHC) Tests
  • 4) By Other Types: Protein Biomarkers; Autoantibody-Based Tests
  • Companies Mentioned: Illumina Inc.; Sysmex Inostics GmbH; Exact Sciences Corporation; Natera Inc; Guardant Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multi Cancer Early Detection Market Characteristics

3. Multi Cancer Early Detection Market Trends And Strategies

4. Multi Cancer Early Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multi Cancer Early Detection Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Multi Cancer Early Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Multi Cancer Early Detection Market Growth Rate Analysis
  • 5.4. Global Multi Cancer Early Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Multi Cancer Early Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Multi Cancer Early Detection Total Addressable Market (TAM)

6. Multi Cancer Early Detection Market Segmentation

  • 6.1. Global Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liquid Biopsy
  • Gene Panel
  • Laboratory Developed Tests (LDT)
  • Other Types
  • 6.2. Global Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Solid Tumors
  • Hematological Malignancies
  • 6.3. Global Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Other End Users
  • 6.4. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Liquid Biopsy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Circulating Tumor Cells (CTC)
  • Circulating Tumor DNA (Ctdna)
  • Exosomes
  • 6.5. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Gene Panel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-Based Panels
  • RNA-Based Panels
  • Multi-Gene Panels
  • 6.6. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Laboratory Developed Tests (LDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR-Based Tests
  • Next-Generation Sequencing (NGS) Tests
  • Immunohistochemistry (IHC) Tests
  • 6.7. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Protein Biomarkers
  • Autoantibody-Based Tests

7. Multi Cancer Early Detection Market Regional And Country Analysis

  • 7.1. Global Multi Cancer Early Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Multi Cancer Early Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multi Cancer Early Detection Market

  • 8.1. Asia-Pacific Multi Cancer Early Detection Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multi Cancer Early Detection Market

  • 9.1. China Multi Cancer Early Detection Market Overview
  • 9.2. China Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multi Cancer Early Detection Market

  • 10.1. India Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multi Cancer Early Detection Market

  • 11.1. Japan Multi Cancer Early Detection Market Overview
  • 11.2. Japan Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multi Cancer Early Detection Market

  • 12.1. Australia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multi Cancer Early Detection Market

  • 13.1. Indonesia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multi Cancer Early Detection Market

  • 14.1. South Korea Multi Cancer Early Detection Market Overview
  • 14.2. South Korea Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multi Cancer Early Detection Market

  • 15.1. Western Europe Multi Cancer Early Detection Market Overview
  • 15.2. Western Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multi Cancer Early Detection Market

  • 16.1. UK Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multi Cancer Early Detection Market

  • 17.1. Germany Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multi Cancer Early Detection Market

  • 18.1. France Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multi Cancer Early Detection Market

  • 19.1. Italy Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multi Cancer Early Detection Market

  • 20.1. Spain Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multi Cancer Early Detection Market

  • 21.1. Eastern Europe Multi Cancer Early Detection Market Overview
  • 21.2. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multi Cancer Early Detection Market

  • 22.1. Russia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multi Cancer Early Detection Market

  • 23.1. North America Multi Cancer Early Detection Market Overview
  • 23.2. North America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multi Cancer Early Detection Market

  • 24.1. USA Multi Cancer Early Detection Market Overview
  • 24.2. USA Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multi Cancer Early Detection Market

  • 25.1. Canada Multi Cancer Early Detection Market Overview
  • 25.2. Canada Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multi Cancer Early Detection Market

  • 26.1. South America Multi Cancer Early Detection Market Overview
  • 26.2. South America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multi Cancer Early Detection Market

  • 27.1. Brazil Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multi Cancer Early Detection Market

  • 28.1. Middle East Multi Cancer Early Detection Market Overview
  • 28.2. Middle East Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multi Cancer Early Detection Market

  • 29.1. Africa Multi Cancer Early Detection Market Overview
  • 29.2. Africa Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multi Cancer Early Detection Market Competitive Landscape And Company Profiles

  • 30.1. Multi Cancer Early Detection Market Competitive Landscape
  • 30.2. Multi Cancer Early Detection Market Company Profiles
    • 30.2.1. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Natera Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Guardant Health Overview, Products and Services, Strategy and Financial Analysis

31. Multi Cancer Early Detection Market Other Major And Innovative Companies

  • 31.1. Core Diagnostics
  • 31.2. Genecast Biotechnology Co. Ltd
  • 31.3. Burning Rock Biotech Limited
  • 31.4. Freenome Holdings Inc.
  • 31.5. Guangzhou AnchorDx Medical Co. Ltd
  • 31.6. Singlera Genomics Incorporated
  • 31.7. Naveris Inc.
  • 31.8. Lucence Health Inc.
  • 31.9. PredOmix Technologies
  • 31.10. Micronoma INC.
  • 31.11. EarlyDiagnostics (EarlyDx)
  • 31.12. Elypta AB
  • 31.13. Predictive Oncology
  • 31.14. ANPAC Bio-Medical Science Co. Ltd
  • 31.15. CanSense Ltd

32. Global Multi Cancer Early Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multi Cancer Early Detection Market

34. Recent Developments In The Multi Cancer Early Detection Market

35. Multi Cancer Early Detection Market High Potential Countries, Segments and Strategies

  • 35.1 Multi Cancer Early Detection Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Multi Cancer Early Detection Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Multi Cancer Early Detection Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer